University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Sir Peter MacCallum Department of Oncology
  • Sir Peter MacCallum Department of Oncology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Sir Peter MacCallum Department of Oncology
  • Sir Peter MacCallum Department of Oncology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

    Thumbnail
    Download
    Published version (1.310Mb)

    Citations
    Scopus
    Web of Science
    Altmetric
    11
    9
    Author
    O'Donnell, T; Christie, EL; Ahuja, A; Buros, J; Aksoy, BA; Bowtell, DDL; Snyder, A; Hammerbacher, J
    Date
    2018-01-22
    Source Title
    BMC Cancer
    Publisher
    BMC
    University of Melbourne Author/s
    Christie, Elizabeth; Bowtell, David
    Affiliation
    Sir Peter MacCallum Department of Oncology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    O'Donnell, T., Christie, E. L., Ahuja, A., Buros, J., Aksoy, B. A., Bowtell, D. D. L., Snyder, A. & Hammerbacher, J. (2018). Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC CANCER, 18 (1), https://doi.org/10.1186/s12885-017-3825-0.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/255620
    DOI
    10.1186/s12885-017-3825-0
    Abstract
    BACKGROUND: Patients with highly mutated tumors, such as melanoma or smoking-related lung cancer, have higher rates of response to immune checkpoint blockade therapy, perhaps due to increased neoantigen expression. Many chemotherapies including platinum compounds are known to be mutagenic, but the impact of standard treatment protocols on mutational burden and resulting neoantigen expression in most human cancers is unknown. METHODS: We sought to quantify the effect of chemotherapy treatment on computationally predicted neoantigen expression for high grade serous ovarian carcinoma patients enrolled in the Australian Ovarian Cancer Study. In this series, 35 of 114 samples were collected after exposure to chemotherapy; 14 are matched with an untreated sample from the same patient. Our approach integrates whole genome and RNA sequencing of bulk tumor samples with class I MHC binding prediction and mutational signatures extracted from studies of chemotherapy-exposed Caenorhabditis elegans and Gallus gallus cells. We additionally investigated the relationship between neoantigens, tumor infiltrating immune cells estimated from RNA-seq with CIBERSORT, and patient survival. RESULTS: Greater neoantigen burden and CD8+ T cell infiltration in primary, pre-treatment samples were independently associated with improved survival. Relapse samples collected after chemotherapy harbored a median of 78% more expressed neoantigens than untreated primary samples, a figure that combines the effects of chemotherapy and other processes operative during relapse. The contribution from chemotherapy-associated signatures was small, accounting for a mean of 5% (range 0-16) of the expressed neoantigen burden in relapse samples. In both treated and untreated samples, most neoantigens were attributed to COSMIC Signature (3), associated with BRCA disruption, Signature (1), associated with a slow mutagenic process active in healthy tissue, and Signature (8), of unknown etiology. CONCLUSION: Relapsed ovarian cancers harbor more predicted neoantigens than primary tumors, but the increase is due to pre-existing mutational processes, not mutagenesis from chemotherapy.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [53102]
    • Sir Peter MacCallum Department of Oncology - Research Publications [1023]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors